Huixian Pan

Background: Circulating tumour DNA (ctDNA), cell-free DNA (cfDNA) and urinary tumour DNA are increasingly studied in bladder cancer and urothelial carcinoma. We mapped the development, knowledge structure and clinical emphasis of this ctDNA/cfDNA-centred literature and assessed its coverage across three bibliographic databases. Methods: Web of Science Core Collection (WoSCC), Scopus and PubMed/MEDLINE were searched on July 31, 2026, for records published in 2008-2025. Reviewer-expanded strategies included liquid biopsy, ctDNA/cfDNA, molecular residual disease, molecular relapse, tumour-informed assays, urinary DNA, methylation, TERT and FGFR3. WoSCC was the primary mapping database; Scopus and PubMed/MEDLINE were coverage comparators. Python, VOSviewer and CiteSpace were used for descriptive and network analyses. Newly retrieved WoSCC records underwent duplicate independent screening and full third-reviewer quality control. Results: The searches retrieved 1,903 WoSCC, 3,201 Scopus and 230 PubMed/MEDLINE records. After WoSCC deduplication and eligibility assessment, 494 records formed the main set and 698 formed a contextual set. The main set received 17,031 citations (median 19; interquartile range 7-42), and annual output reached 82 records in 2025. Scopus covered 456/494 main records and PubMed/MEDLINE covered 93/494. Among 557 newly assessed records, the reviewers initially agreed on 433 (77.7%; Cohen’s kappa, 0.620); all records then underwent third-reviewer full-text quality control. Conclusions: The expanded search identifies a larger DNA-focused literature than the original strategy and confirms unequal database coverage. Thematic clusters and citation bursts trace a shift from early methylation-marker research towards ctDNA-based molecular residual disease assessment and perioperative treatment stratification. Bibliometric prominence describes research activity, not diagnostic accuracy, predictive validity or treatment benefit.

To evaluate the clinical efficacy and safety of combined sacral magnetic stimulation (SMS) and bladder electrical stimulation (ES) in treating post-stroke urgency urinary incontinence (UUI). We retrospectively enrolled 90 patients with post-stroke UUI, divided into ES, SMS, and SMS + ES groups (n = 30 each). Urodynamic parameters, voiding diaries, quality of life scales (ICIQ-SF, ICIQ-QoL, SAS), Patient Global Impression of Improvement (PGI-I), urinary tract infection (UTI) incidence, and overall response rates were compared before and 1 month after treatment. The SMS + ES group demonstrated comprehensive therapeutic advantages. Urodynamically, this group showed significantly greater maximum bladder capacity (408.5 ± 70.1 mL), lower postvoid residual urine volume (75.2 ± 53.4 mL), and lower detrusor pressure at maximum flow (28.4 ± 6.5 cmH₂O) compared to single-therapy groups (all P < 0.01). Clinically, the combined group showed the most significant improvements in 24-h incontinence episodes, ICIQ-SF, ICIQ-QoL, and SAS scores (all P < 0.01), along with the best PGI-I scores. The UTI incidence was 3.3% in the SMS + ES group, significantly lower than the 13.3% in the ES group (P < 0.05). The overall response rate was 93.3% in the SMS + ES group, significantly higher than in the ES (66.7%) and SMS (73.3%) groups (P < 0.05). Combined SMS and ES therapy synergistically improves storage and voiding function, alleviates anxiety, reduces UTI risk, and significantly enhances quality of life in post-stroke UUI patients, demonstrating superior efficacy over either therapy alone.